Research Progress on Mesenchymal Stem Cells in the Treatment of Premature Ovarian Failure

doi:10.12280/gjszjk.20260115

Abstract

Abstract:

Premature ovarian failure (POF) is a major endocrine disorder leading to female infertility and long?term health risks, with limited efficacy of conventional therapies. Mesenchymal stem cells (MSCs) offer new therapeutic avenues for POF due to the multidirectional differentiation, paracrine activity, immunomodulation, and homing capacity. MSCs from various tissue sources (umbilical cord, bone marrow, menstrual blood, adipose tissue, amnion, urine, etc.) have distinct advantages in efficacy and accessibility. Strategies including genetic engineering modification, preconditioning, extracellular vesicles, and biomaterial-based scaffolds further enhance the reparative potential of MSCs. Preliminary clinical studies have demonstrated the safety and feasibility of MSCs, yet challenges remain, such as standardization, heterogeneous efficacy, and long-term safety. Future directions, such as precision therapy, cell-free approaches, ovarian organoid construction and interdisciplinary integration, will promote the clinical translation.

Key words: Primary ovarian insufficiency, Mesenchymal stem cells, Mesenchymal stem cell transplantation, Regenerative medicine, Premature ovarian failure

LI Huan, YANG Li-juan, HU Shuo-nan, LI Lin, XIONG Qing. Research Progress on Mesenchymal Stem Cells in the Treatment of Premature Ovarian Failure[J]. Journal of International Reproductive Health/Family Planning, 2026, 45(4): 331-335.

References 41

[1]	Takahashi A, Yousif A, Hong L, et al. Premature ovarian insufficiency: pathogenesis and therapeutic potential of mesenchymal stem cell[J]. J Mol Med(Berl), 2021, 99(5):637-650. doi: 10.1007/ s00109-021-02055-5.
[2]	Shi YQ, Zhu XT, Zhang SN, et al. Premature ovarian insufficiency: a review on the role of oxidative stress and the application of antioxidants[J]. Front Endocrinol(Lausanne), 2023, 14:1172481. doi: 10.3389/fendo.2023.1172481.
[3]	Vijayalakshmi SR, Shagun A. Genetics of premature ovarian failure[J]. Genet Clin, 2018, 11(2): 10-17.
[4]	Panay N, Anderson RA, Bennie A, et al. Evidence-based guideline: premature ovarian insufficiency[J]. Hum Reprod Open, 2024, 2024(4):hoae065. doi: 10.1093/hropen/hoae065.
[5]	Pepin A, Chesnokova A, Pishko A, et al. Hormone Replacement Therapy in Patients with Gynecologic Cancer and Radiation-Induced Premature Ovarian Insufficiency[J]. Int J Radiat Oncol Biol Phys, 2025, 121(4):1042-1052. doi: 10.1016/j.ijrobp.2024. 10.023.
[6]	Yuan Z, Zhang Y, He X, et al. Engineering mesenchymal stem cells for premature ovarian failure: overcoming challenges and innovating therapeutic strategies[J]. Theranostics, 2024, 14(17):6487-6515. doi: 10.7150/thno.102641. pmid: 39479455
[7]	Fu YX, Ji J, Shan F, et al. Human mesenchymal stem cell treatment of premature ovarian failure: new challenges and opportunities[J]. Stem Cell Res Ther, 2021, 12(1):161. doi: 10.1186/s13287-021-02212-0.
[8]	Bahrehbar K, Khanjarpoor Malakhond M, Gholami S. Tracking of human embryonic stem cell-derived mesenchymal stem cells in premature ovarian failure model mice[J]. Biochem Biophys Res Commun, 2021, 577:6-11. doi: 10.1016/j.bbrc.2021.08.063.
[9]	Huang Y, Zhu M, Liu Z, et al. Bone marrow mesenchymal stem cells in premature ovarian failure: Mechanisms and prospects[J]. Front Immunol, 2022, 13:997808. doi: 10.3389/fimmu.2022. 997808.
[10]	Tian C, Ye L, Zhao X, et al. Umbilical cord mesenchymal stem cells: A novel approach to intervention of ovarian ageing[J]. Regen Ther, 2024, 26:590-598. doi: 10.1016/j.reth.2024.08.006. pmid: 39246700
[11]	Zhang M, Xie T, Dai W, et al. Umbilical Cord Mesenchymal Stem Cells Ameliorate Premature Ovarian Insufficiency in Rats[J]. Evid Based Complement Alternat Med, 2022, 2022:9228456. doi: 10.1155/2022/9228456.
[12]	Dai W, Yang H, Xu B, et al. Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) alleviate excessive autophagy of ovarian granular cells through VEGFA/PI3K/AKT/mTOR pathway in premature ovarian failure rat model[J]. J Ovarian Res, 2023, 16(1):198. doi: 10.1186/s13048-023-01278-z. pmid: 37777781
[13]	He J, Ao C, Li M, et al. Clusterin-carrying extracellular vesicles derived from human umbilical cord mesenchymal stem cells restore the ovarian function of premature ovarian failure mice through activating the PI3K/AKT pathway[J]. Stem Cell Res Ther, 2024, 15(1):300. doi: 10.1186/s13287-024-03926-7. pmid: 39272156
[14]	Shen J, Wu L, Shi X, et al. Transplantation of the LRP1high subpopulation of human umbilical cord-derived mesenchymal stem cells improves ovarian function in mice with premature ovarian failure and aged mice[J]. Stem Cell Res Ther, 2024, 15(1):64. doi: 10.1186/s13287-024-03660-0.
[15]	Yang Y, Tang L, Xiao Y, et al. miR-21-5p-loaded bone mesenchymal stem cell-derived exosomes repair ovarian function in autoimmune premature ovarian insufficiency by targeting MSX1[J]. Reprod Biomed Online, 2024, 48(6):103815. doi: 10.1016/j.rbmo.2024.103815.
[16]	Ahmed AI, Dowidar MF, Negm AF, et al. Bone marrow mesenchymal stem cells expressing Neat-1, Hotair-1, miR-21, miR-644, and miR-144 subsided cyclophosphamide-induced ovarian insufficiency by remodeling the IGF-1-kisspeptin system, ovarian apoptosis, and angiogenesis[J]. J Ovarian Res, 2024, 17(1):184. doi: 10.1186/s13048-024-01498-x. pmid: 39267091
[17]	El-Derany MO, Said RS, El-Demerdash E. Bone Marrow-Derived Mesenchymal Stem Cells Reverse Radiotherapy-Induced Premature Ovarian Failure: Emphasis on Signal Integration of TGF-β, Wnt/β-Catenin and Hippo Pathways[J]. Stem Cell Rev Rep, 2021, 17(4):1429-1445. doi: 10.1007/s12015-021-10135-9. pmid: 33594662
[18]	Garg K, Zilate S. Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Infertility Due to Premature Ovarian Failure[J]. Cureus, 2022, 14(10):e30529. doi: 10.7759/cureus. 30529.
[19]	Zhang S, Yahaya BH, Pan Y, et al. Menstrual blood-derived endometrial stem cell, a unique and promising alternative in the stem cell-based therapy for chemotherapy-induced premature ovarian insufficiency[J]. Stem Cell Res Ther, 2023, 14(1):327. doi: 10.1186/s13287-023-03551-w. pmid: 37957675
[20]	Sadiasa A, Werkmeister JA, Gurung S, et al. Steps towards the clinical application of endometrial and menstrual fluid mesenchymal stem cells for the treatment of gynecological disorders[J]. Expert Opin Biol Ther, 2025, 25(3):285-307. doi: 10.1080/14712598.2025.2465826.
[21]	Yamchi NN, Rahbarghazi R, Bedate AM, et al. Menstrual blood CD146+ mesenchymal stem cells reduced fibrosis rate in the rat model of premature ovarian failure[J]. Cell Biochem Funct, 2021, 39(8):998-1008. doi: 10.1002/cbf.3669.
[22]	Zafardoust S, Kazemnejad S, Darzi M, et al. Intraovarian Administration of Autologous Menstrual Blood Derived-Mesenchymal Stromal Cells in Women with Premature Ovarian Failure[J]. Arch Med Res, 2023, 54(2):135-144. doi: 10.1016/j.arcmed.2022.12.015.
[23]	Li DY, Li YM, Lv DY, et al. Enhanced interaction between genome-edited mesenchymal stem cells and platelets improves wound healing in mice[J]. J Tissue Eng, 2024, 15:20417314241268917. doi: 10.1177/20417314241268917.
[24]	Almeida Galvão MG, Andrade Santos BM, Moreira Aguiar C, et al. solation, In Vitro Expansion, and Characterization of Mesenchymal Stem Cells from Mouse Epididymal Adipose Tissue[J]. J Vis Exp, 2024,203:e65722. doi: 10.3791/65722.
[25]	Ma X, Dong M, Chen B, et al. Innovative Mechanical Processing of Adipose Tissue: A Comparative Evaluation of Microfat and Concentrated Micronized Fat for Superficial Fat Grafting[J]. Aesthetic Plast Surg, 2025, 49(12):3480-3493. doi: 10.1007/s00266-024-04634-6. pmid: 39762393
[26]	Nouri N, Aghebati-Maleki L, Yousefi M. Adipose-Derived Mesenchymal Stem Cells: A Promising Tool in the Treatment of pre mature ovarian failure[J]. J Reprod Immunol, 2021, 147:103363. doi: 10.1016/j.jri.2021.103363.
[27]	Pouryousefi-Koodehi T, Shayegan S, Hashemi S, et al. Can mesenchymal stem cells derived from adipose tissue and their conditioned medium improve ovarian functions? A mini-review[J]. Zygote, 2022, 30(5):589-592. doi: 10.1017/S0967199422000235.
[28]	Un B, Cetinkaya-Un B, Akpolat M, et al. The effects of human amnion membrane-derived mesenchymal stem cells conditioned medium on ionizing radiation-induced premature ovarian failure and endoplasmic reticulum stress-related apoptosis mechanism[J]. Eur J Obstet Gynecol Reprod Biol, 2023, 288:191-197. doi: 10.1016/j.ejogrb.2023.08.001. pmid: 37566962
[29]	Gu HC, Wang LF, Zhang YW, et al. Human urine stem cells protect against cyclophosphamide-induced premature ovarian failure by inhibiting SLC1A4-mediated outflux of intracellular serine in ovarian granulosa cells[J]. Cell Mol Biol Lett, 2025, 30(1):21. doi: 10.1186/s11658-025-00701-1.
[30]	Billing AM, Dib SS, Bhagwat AM, et al. A Systems-level Characterization of the Differentiation of Human Embryonic Stem Cells into Mesenchymal Stem Cells[J]. Mol Cell Proteomics, 2019, 18(10):1950-1966. doi: 10.1074/mcp.RA119.001356. pmid: 31332097
[31]	Yimamuyushan S, Shi S, Muheremu A, et al. PEDF-Expressing mesenchymal stem cells restore ovarian function via Tim-3-Mediated immune modulation in primary ovarian failure[J]. J Ovarian Res, 2025, 18(1):182. doi: 10.1186/s13048-025-01778-0. pmid: 40814064
[32]	Tuong TVN, Duy KP, Que THC, et al. Mesenchymal stem cells and the angiogenic regulatory network with potential incorporation and modification for therapeutic development[J]. Biocell, 2024, 48(2):173-189. doi: 10.32604/BIOCELL.2023.043664.
[33]	Zhao YD, Huang YC, Li WS. Searching for the optimal precondition procedure for mesenchymal stem/stromal cell treatment: Facts and perspectives[J]. World J Stem Cells, 2024, 16(6):615-618. doi: 10.4252/wjsc.v16.i6.615.
[34]	Jalali L, Allahveisie A, Rezaei S, et al. Effect of preconditioning of human umbilical cord mesenchymal stem cells with hydrogen peroxide on the therapeutic potential of MSCs in the cyclophosphamide -induced premature ovarian failure mice model[J]. Taiwan J Obstet Gynecol, 2023, 62(5):667-676. doi: 10.1016/j.tjog.2023.07.007. pmid: 37678993
[35]	Qu Q, Liu L, Cui Y, et al. miR-126-3p containing exosomes derived from human umbilical cord mesenchymal stem cells promote angiogenesis and attenuate ovarian granulosa cell apoptosis in a preclinical rat model of premature ovarian failure[J]. Stem Cell Res Ther, 2022, 13(1):352. doi: 10.1186/s13287-022-03056-y. pmid: 35883161
[36]	Zhou Y, Huang J, Zeng L, et al. Human mesenchymal stem cells derived exosomes improve ovarian function in chemotherapy-induced premature ovarian insufficiency mice by inhibiting ferroptosis through Nrf2/GPX4 pathway[J]. J Ovarian Res, 2024, 17(1):80. doi: 10.1186/s13048-024-01403-6. pmid: 38622725
[37]	Li N, Fan X, Liu L, et al. Therapeutic effects of human umbilical cord mesenchymal stem cell-derived extracellular vesicles on ovarian functions through the PI3K/Akt cascade in mice with premature ovarian failure[J]. Eur J Histochem, 2023, 67(3):3506. doi: 10.4081/ejh.2023.3506.
[38]	Song Y, Wu J, Liu Y, et al. The remodeling of ovarian function: targeted delivery strategies for mesenchymal stem cells and their derived extracellular vesicles[J]. Stem Cell Res Ther, 2024, 15(1):90. doi: 10.1186/s13287-024-03704-5. pmid: 38539206
[39]	Dai F, Liu H, He J, et al. Model construction and drug therapy of primary ovarian insufficiency by ultrasound-guided injection[J]. Stem Cell Res Ther, 2024, 15(1):49. doi: 10.1186/s13287-024-03646-y. pmid: 38378684
[40]	Saharkhiz N, Hajizadeh N, Alkhafaji JS, et al. Evaluation of the therapeutic effect of very small stem cells from peripheral blood on the treatment of Premature Ovarian Failure: A pilot study[J]. JBRA Assist Reprod, 2024, 28(3):424-429. doi: 10.5935/1518-0557.20240021. pmid: 38640352
[41]	Yan L, Wu Y, Li L,etal. Clinical analysis of human umbilical cord mesenchymal stem cell allotransplantation in patients with premature ovarian insufficiency[J]. Cell Prolif, 2020, 53(12):e12938. doi: 10.1111/cpr.12938.